Persistent Asset Partners Ltd Takes Position in Abivax SA Sponsored ADR $ABVX

Persistent Asset Partners Ltd acquired a new position in Abivax SA Sponsored ADR (NASDAQ:ABVX) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 9,604 shares of the company’s stock, valued at approximately $815,000.

Several other large investors have also recently bought and sold shares of the stock. Octagon Capital Advisors LP boosted its holdings in Abivax by 3.0% in the 2nd quarter. Octagon Capital Advisors LP now owns 1,267,000 shares of the company’s stock valued at $9,693,000 after purchasing an additional 37,000 shares during the period. Millennium Management LLC lifted its stake in shares of Abivax by 6.0% in the first quarter. Millennium Management LLC now owns 987,414 shares of the company’s stock valued at $6,171,000 after buying an additional 56,235 shares during the period. Boothbay Fund Management LLC grew its position in Abivax by 52.5% during the second quarter. Boothbay Fund Management LLC now owns 870,438 shares of the company’s stock worth $6,659,000 after buying an additional 299,770 shares in the last quarter. Aberdeen Group plc increased its stake in Abivax by 10.8% during the third quarter. Aberdeen Group plc now owns 787,417 shares of the company’s stock valued at $66,852,000 after acquiring an additional 76,901 shares during the period. Finally, Saturn V Capital Management LP raised its holdings in Abivax by 12.6% in the 2nd quarter. Saturn V Capital Management LP now owns 622,479 shares of the company’s stock valued at $4,762,000 after acquiring an additional 69,553 shares in the last quarter. 47.91% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on ABVX shares. Morgan Stanley lifted their price objective on Abivax from $101.00 to $145.00 and gave the stock an “overweight” rating in a report on Friday, January 9th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Abivax in a research report on Wednesday, January 21st. Truist Financial set a $140.00 price target on shares of Abivax in a report on Monday, November 24th. Guggenheim restated a “buy” rating and issued a $175.00 price objective on shares of Abivax in a research note on Thursday, December 18th. Finally, BTIG Research lifted their target price on shares of Abivax from $120.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, January 8th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $137.00.

Abivax Stock Performance

Abivax stock opened at $130.24 on Friday. Abivax SA Sponsored ADR has a 1 year low of $4.77 and a 1 year high of $148.83. The company’s 50-day moving average is $123.06 and its two-hundred day moving average is $103.51. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03. The company has a market cap of $10.30 billion, a PE ratio of -31.16 and a beta of 0.79.

Abivax (NASDAQ:ABVX) last posted its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The company had revenue of ($4.92) million for the quarter. Equities analysts anticipate that Abivax SA Sponsored ADR will post -2.83 earnings per share for the current year.

Abivax Company Profile

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.